| Literature DB >> 33114104 |
Dong-Hee Ryu1, Yu-Mi Lee2, Ji Mi Park3, Won Young Tak4, Nam-Soo Hong2,3.
Abstract
Ulleung county is a small island on the eastern side of the Korean peninsula. The Ulleung Liver Cancer Prevention and Management Project was launched in order to minimize newly developing liver cancer within this region. Population-based regional cancer registry data were analyzed to investigate the status and characteristics of registered liver cancer patients. The Interagency Workgroup of the project provided a special screening program from 1 November to 3 November 2018, and from 23 April to 25 April 2019, undertaking liver cancer screening and health behavior surveys. Logistic regression analysis was used to determine factors associated with recent liver cancer screening. In Ulleung county, hepatocellular carcinoma was identified as the main type of liver cancer, accompanied by a high incidence of hepatitis B. Approximately 25.0% of the participants were not aware of their liver condition. People who were aware of their liver condition and those who reported a general understanding of hepatitis B were more likely to have undergone recent liver cancer screening. To prevent the development and spread of the disease in the community, adequate infrastructure for cancer screening and an enhanced monitoring system are required, along with measures to create awareness to periodically determine liver condition in high-risk groups.Entities:
Keywords: awareness; early detection of cancer; health behavior; liver neoplasm; residence characteristics
Mesh:
Year: 2020 PMID: 33114104 PMCID: PMC7660348 DOI: 10.3390/ijerph17217757
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Five-year standardized incidence ratios (SIRs) for Daegu, Gyeongbuk (excluding Ulleung), and Ulleung county (2006–2016).
| Year | Region | Number of Registered Liver Cancer Patients | Total | Male | Female |
|---|---|---|---|---|---|
| 2002–2006 | DG | 3699 | 1.03 (0.95–1.10) | 1.04 (0.96–1.13) | 1.03 (0.89–1.19) |
| GBE | 5505 | 1.10 (1.04–1.17) | 1.13 (1.06–1.21) | 1.04 (0.92–1.16) | |
| Ulleung | 43 | 1.94 (0.86–3.45) | 1.91 (0.73–3.64) | 1.80 (0.17–5.15) | |
| 2007–2011 | DG | 3847 | 0.97 (0.91–1.04) | 0.98 (0.90–1.06) | 0.99 (0.86–1.14) |
| GBE | 5531 | 1.07 (1.00–1.13) | 1.10 (1.03–1.18) | 0.98 (0.87–1.10) | |
| Ulleung | 43 | 1.75 (0.77–3.12) | 1.72 (0.66–3.28) | 1.60 (0.15–4.60) | |
| 2012–2016 | DG | 3621 | 0.92 (0.86–0.99) | 0.95 (0.87–1.03) | 0.90 (0.77–1.04) |
| GBE | 5396 | 1.05 (0.99–1.12) | 1.08 (1.01–1.16) | 0.99 (0.87–1.11) | |
| Ulleung | 46 | 1.96 (0.90–3.43) | 1.94 (0.78–3.60) | 1.72 (0.16–4.93) |
Values are presented as a 5-year standardized incidence ratio (95% confidence interval). The standardization was completed with indirect adjustment, and the index populations of mid-years were used. Abbreviations: DG, Daegu; GBE, Gyeongbuk (excluding Ulleung).
Characteristics of patients diagnosed with malignant neoplasm of the liver and intrahepatic bile ducts (C22) (2006–2016).
| Category | Unmatched | Matched * | ||||||
|---|---|---|---|---|---|---|---|---|
| DG | GBE | Ulleung |
| DG | GBE | Ulleung |
| |
| Total | 8244 | 12,046 | 91 | 91 | 91 | 91 | ||
| Sex | ||||||||
| Male | 6187 (75.1) | 9018 (74.9) | 71 (78.0) | 0.76 | 65 (71.4) | 69 (75.8) | 71 (78.0) | 0.58 |
| Female | 2057 (24.9) | 3028 (25.1) | 20 (22.0) | 26 (28.6) | 22 (24.2) | 20 (22.0) | ||
| Age | ||||||||
| <50 | 1357 (16.5) | 1562 (13.0) | 11 (12.1) | <0.01 | 23 (25.3) | 22 (24.2) | 11 (12.1) | 0.27 |
| 50–59 | 2440 (29.6) | 3012 (25.0) | 28 (30.8) | 21 (23.1) | 20 (22.0) | 28 (30.8) | ||
| 60–69 | 2193 (26.6) | 3210 (26.7) | 30 (33.0) | 27 (29.7) | 24 (26.4) | 30 (33.0) | ||
| ≥70 | 2254 (27.3) | 4262 (35.4) | 22 (24.2) | 20 (22.0) | 25 (27.5) | 22 (24.2) | ||
| Primary tumor site 1 | ||||||||
| Liver | 6740 (81.8) | 9412 (78.1) | 78 (85.7) | <0.01 | 75 (82.4) | 73 (80.2) | 78 (85.7) | 0.61 |
| Intrahepatic bile duct | 1504 (18.2) | 2634 (21.9) | 13 (14.3) | 16 (17.6) | 18 (19.8) | 13 (14.3) | ||
| Histological diagnosis 1 | ||||||||
| HCC | 6419 (77.9) | 8845 (73.4) | 78 (85.7) | <0.01 | 71 (78.0) | 71 (78.0) | 78 (85.7) | 0.46 |
| CC | 1115 (13.5) | 1675 (13.9) | 8 (8.8) | 5 (5.5) | 4 (4.4) | 8 (8.8) | ||
| Combined HCC–CC | 82 (1.0) | 87 (0.7) | 1 (1.1) | 2 (2.2) | 2 (2.2) | 1 (1.1) | ||
| Klatskin tumor | 201 (2.4) | 456 (3.8) | 1 (1.1) | 5 (5.5) | 9 (9.9) | 1 (1.1) | ||
| Adenocarcinoma | 103 (1.3) | 228 (1.9) | 2 (2.2) | 2 (2.2) | 0 (0.0) | 2 (2.2) | ||
| Neoplasm | 213 (2.6) | 572 (4.8) | 0 (0.0) | 4 (4.4) | 5 (5.5) | 0 (0.0) | ||
| Other: liver or intrahepatic duct | 75 (0.9) | 119 (1.0) | 1 (1.1) | 1 (1.1) | 0 (0.0) | 1 (1.1) | ||
| Other: other organs | 36 (0.4) | 64 (0.5) | 0 (0.0) | 1 (1.1) | 0 (0.0) | 0 (0.0) | ||
| Summary stage | ||||||||
| Localized | 4531 (55.0) | 5363 (44.5) | 48 (52.8) | <0.01 | 47 (51.7) | 34 (37.4) | 48 (52.8) | 0.04 |
| Regional | 1748 (21.2) | 2874 (23.9) | 23 (25.3) | 23 (25.3) | 25 (27.5) | 23 (25.3) | ||
| Distant | 1186 (14.4) | 1790 (14.9) | 10 (11.0) | 12 (13.2) | 8 (8.8) | 10 (11.0) | ||
| Unknown | 779 (9.5) | 2019 (16.8) | 10 (11.0) | 9 (9.9) | 24 (26.4) | 10 (11.0) | ||
| All-cause survival status 2 | ||||||||
| Survived | 2119 (25.7) | 2808 (23.3) | 28 (30.8) | <0.01 | 5 (5.5) | 14 (15.4) | 28 (30.8) | <0.01 |
| Deceased | 6125 (74.3) | 9238 (76.7) | 63 (69.2) | 86 (94.5) | 77 (84.6) | 63 (69.2) | ||
| Cause of death (deceased only) | ||||||||
| Malignant neoplasm of liver and intrahepatic bile duct | 5103 (83.3) | 7399 (80.1) | 46 (73.0) | <0.01 | 74 (86.1) | 62 (80.5) | 46 (73.0) | 0.14 |
| Others | 1022 (16.7) | 1839 (19.9) | 17 (27.0) | 12 (14.0) | 15 (19.5) | 17 (27.0) | ||
| Survival time3 | ||||||||
| Mean ± SD (years) | 7.3 ± 22.1 | 6.8 ± 10.9 | 5.7 ± 2.9 | 0.26 | 11.2 ± 1.9 | 11.2 ± 2.4 | 5.7 ± 2.9 | <0.01 |
Values are presented as number (%). * Propensity score matching analysis was performed. Logistic regression was performed with sex and age as covariates, and the minimum distance method was used to match patients with similar scores. 1 Primary tumor site and histological diagnosis were classified by the code ICD-O-3. 2 Survival status: as of 30 November 2018. 3 Survival time: survival duration (years) of patients whose cause of death was malignant neoplasm of the liver and intrahepatic bile duct (C22). Abbreviations: DG, Daegu; GBE, Gyeongbuk (excluding Ulleung); HCC, hepatocellular carcinoma; CC, cholangiocarcinoma; SD, standard deviation.
Sociodemographic characteristics and risk perception in high-risk individuals in Ulleung (n = 53).
| Category | Subgroup | Total | Liver Cancer Screening Within the Past Year | |||||
|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| Crude OR (95% CI) | Adjusted * OR (95% CI) | ||
| Total | 53 | 100.0 | 31 | 58.5 | - | - | - | |
| Sociodemographic characteristics | ||||||||
| Sex | Male | 28 | 52.8 | 14 | 50.0 | 0.18 | 0.47 (0.15–1.44) | - |
| Female | 25 | 47.2 | 17 | 68.0 | Ref | - | ||
| Age | <50 | 13 | 24.5 | 5 | 38.5 | 0.27 | 0.31 (0.05–1.85) | - |
| 50–59 | 13 | 24.5 | 7 | 53.9 | 0.58 (0.10–3.40) | - | ||
| 60–69 | 18 | 34.0 | 13 | 72.2 | 1.30 (0.23–7.32) | - | ||
| ≥70 | 9 | 17.0 | 6 | 66.7 | Ref | - | ||
| Residence duration in Ulleung | <10 years | 8 | 15.1 | 5 | 62.5 | 0.99 | Ref | Ref |
| ≥10 years | 45 | 84.9 | 26 | 57.8 | 0.82 (0.17–3.86) | 0.26 (0.03–1.98) | ||
| Education | ≤Elementary | 15 | 28.3 | 12 | 80.0 | 0.04 | 1.33 (0.17–10.25) | |
| Jr. high school | 10 | 18.9 | 6 | 60.0 | 0.50 (0.07–3.85) | |||
| High school | 20 | 37.7 | 7 | 35.0 | 0.18 (0.03–1.14) | |||
| ≥College | 8 | 15.1 | 6 | 75.0 | Ref | |||
| Monthly income (1000 KRW) | <500 | 12 | 22.6 | 8 | 66.7 | 0.04 | 1.50 (0.22–10.22) | 0.38 (0.03–4.43) |
| 500–1000 | 10 | 18.9 | 7 | 70.0 | 1.75 (0.23–13.16) | 0.55 (0.05–6.09) | ||
| 1000–2000 | 13 | 24.5 | 10 | 76.9 | 2.50 (0.35–18.04) | 1.50 (0.18–12.76) | ||
| 2000–3000 | 11 | 20.8 | 2 | 18.2 | 0.17 (0.02–1.42) | 0.08 (0.01–0.92) | ||
| ≥3000 | 7 | 13.2 | 4 | 57.1 | Ref | Ref | ||
| Risk perception | ||||||||
| Liver condition awareness | Yes | 40 | 75.5 | 29 | 72.5 | <0.01 | 14.50 (2.76–76.15) | 18.84 (2.82–126.14) |
| No | 13 | 24.5 | 2 | 15.4 | Ref | Ref | ||
| General understanding about | Hepatitis B (Yes) | 29 | 54.7 | 20 | 69.0 | 0.09 | 2.63 (0.85–8.08) | 8.70 (1.56–47.92) |
| Hepatitis B (No) | 24 | 45.3 | 11 | 45.8 | Ref | Ref | ||
| Hepatitis C (Yes) | 15 | 28.3 | 9 | 60.0 | 0.89 | 1.09 (0.32–3.69) | 1.40 (0.37–5.26) | |
| Hepatitis C (No) | 38 | 71.7 | 22 | 57.9 | Ref | Ref | ||
| Liver cirrhosis (Yes) | 30 | 56.6 | 17 | 56.7 | 0.76 | 0.84 (0.28–2.54) | 1.06 (0.29–3.93) | |
| Liver cirrhosis (No) | 23 | 43.4 | 14 | 60.9 | Ref | Ref | ||
* Adjusted for sex and age. Abbreviations: OR, odds ratio; CI, confidence interval; Ref, reference; KRW, the currency of Korea (KRW 1000 is approximately USD 1).
Health behaviors of high-risk individuals in Ulleung (n = 53).
| Category | Subgroup | Total | Liver Cancer Screening within the Past Year | |||||
|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| Crude OR (95% CI) | Adjusted * OR (95% CI) | ||
| Total | 53 | 100.0 | 31 | 58.5 | - | - | - | |
| Current health behaviors | ||||||||
| Current smoking | Yes | 13 | 24.5 | 4 | 30.8 | 0.02 | 0.21 (0.06–0.83) | 0.26 (0.05–1.47) |
| No | 40 | 75.5 | 27 | 67.5 | Ref | Ref | ||
| Heavy alcohol consumption | Yes | 11 | 20.8 | 6 | 54.6 | 0.99 | 0.82 (0.21–3.11) | 1.12 (0.26–4.83) |
| No | 42 | 79.3 | 25 | 59.5 | Ref | Ref | ||
| BMI | ≥25 | 29 | 54.7 | 17 | 58.6 | 0.98 | 1.01 (0.34–3.03) | 0.93 (0.29–2.94) |
| <25 | 24 | 45.3 | 14 | 58.3 | Ref | Ref | ||
| Moderate exercise | No | 34 | 64.2 | 18 | 52.9 | 0.27 | 0.52 (0.16–1.69) | 0.39 (0.10–1.50) |
| Yes | 19 | 35.9 | 13 | 68.4 | Ref | Ref | ||
| Risky health behaviors | ||||||||
| Sharing personal sanitary products with others 1 | Yes | 8 | 15.1 | 4 | 50.0 | 0.70 | 0.67 (0.15–3.01) | 0.39 (0.07–2.13) |
| No | 45 | 84.9 | 27 | 60.0 | Ref | Ref | ||
| Procedures involving questionable hygiene 2 | Yes | 20 | 37.7 | 14 | 70.0 | 0.19 | 2.20 (0.68–7.11) | 1.68 (0.42–6.79) |
| No | 33 | 62.3 | 17 | 51.5 | Ref | Ref | ||
| Intercourse with non-spouse | Yes | 7 | 13.2 | 5 | 71.4 | 0.69 | 1.92 (0.34–10.96) | 4.55 (0.60–34.75) |
| No | 46 | 86.8 | 26 | 56.5 | Ref | Ref | ||
| Medical history | ||||||||
| HBV vaccination | No 3 | 33 | 62.3 | 19 | 57.6 | 0.86 | 0.91 (0.29–2.80) | 0.87 (0.26–2.87) |
| Yes | 20 | 37.7 | 12 | 60.0 | Ref | Ref | ||
| Diagnosis of | Cancer | 2 | 3.8 | 2 | 100.0 | 0.51 | - | - |
| STI | 0 | 0.0 | - | - | - | - | - | |
| Medical procedure | Blood transfusion | 5 | 9.4 | 3 | 60.0 | 0.99 | 1.07 (0.16–7.01) | 0.87 (0.12–6.49) |
| Dialysis | 0 | 0.0 | - | - | - | - | - | |
| Family history of | Cancer 4 | 28 | 52.8 | 17 | 60.7 | 0.72 | 1.21 (0.41–3.63) | 1.48 (0.44–4.99) |
* Adjusted for sex and age. 1 Sharing personal sanitary products (razor, nail clipper, toothbrush) with others: sharing razor, 1 (1.9%); sharing nail clipper, 8 (15.1%); sharing both razor and nail clipper, 1 (1.9%); sharing toothbrush, 0 (0.0%). 2 Procedures with questionable hygiene (tattooing, piercing, illegal drug injection, acupuncture/cupping at non-medical facilities): tattooing, 15 (28.3%); piercing, 7 (13.2%); both tattooing and piercing, 3 (5.7%); illegal drug injection, 0 (0.0%); acupuncture/cupping at non-medical facilities, 1 (1.9%). 3 Included four response failures. 4 Family members include parents, siblings, and children. Abbreviations: OR, odds ratio; CI, confidence interval; Ref, reference; BMI, body mass index; HBV, hepatitis B virus; STI, sexually transmitted infection.